You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

 

Online download statistics by month:

Online download statistics by month: June 2020 to June 2025

AbstractFullPdf
Jun 202022722790
Jul 202015015069
Aug 202011511560
Sep 202013913973
Oct 202014014084
Nov 202020520770
Dec 202019919942
Jan 202120120171
Feb 202123023070
Mar 202124724792
Apr 202125025197
May 202119819859
Jun 202115715762
Jul 202115915964
Aug 202125625676
Sep 202128528559
Oct 202122722798
Nov 202125325296
Dec 202119619660
Jan 202222923268
Feb 202221422765
Mar 202228929569
Apr 202221222043
May 202222222555
Jun 202216817454
Jul 202213514349
Aug 202216917345
Sep 202215616261
Oct 202218819263
Nov 202216616755
Dec 202210710946
Jan 202322622947
Feb 202318518754
Mar 202318919057
Apr 202314514783
May 202311912040
Jun 202314414434
Jul 202315015054
Aug 202315415694
Sep 202317817956
Oct 202330130357
Nov 202313113272
Dec 202310410556
Jan 2024909250
Feb 202415715755
Mar 2024181184131
Apr 202414214292
May 2024909057
Jun 2024999966
Jul 202413713944
Aug 202410110146
Sep 2024939362
Oct 202412712758
Nov 202413513753
Dec 202410410461
Jan 202511211657
Feb 20259610059
Mar 2025969657
Apr 202520220582
May 202516116371
Jun 2025909047
Total10328104323917